Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Tencentson Feb 21, 2024 3:04pm
53 Views
Post# 35891564

RE:Let's be more balanced and positive

RE:Let's be more balanced and positiveWe have yet to see what capital aezs can bring to the merger 
it has not been described anywhere or by anyone
it Could be the 50 m cash on hand
but this will be eaten up by expected losses over the 2024/2025
it could be a diagnostics deal
so far discussions are going on since 2022
its likely that as stonebridge and nova concluded the diagnostic had little potentiel, a smaller size player might be interested . Such a player will not be able to make upfront payments and may ask for un upfront payment to support marketing efforts
There are many lights maybe could ets in the discissions
what we need is what when and how much 
<< Previous
Bullboard Posts
Next >>